Med. praxi. 2010;7(5):209-215

Metabolic syndrome in nephrology

prof.MUDr.Vladimír Teplan, DrSc.
Klinika nefrologie TC IKEM a Subkatedra nefrologie IPVZ Praha

Metabolic syndrome represents a serious risk factor for renal injury. In addition to an increased risk of cardiovascular disease and diabetic

complications, it can lead to the development of glomerulopathies and their further progression. It also increases the risk of occurrence

of renal calculi and kidney tumours. Hypertension in metabolic syndrome and obesity is associated with sodium retention and increased

activity of the sympathetic nervous system. Given the changes in dietary habits and a lack of physical activity worldwide, the increase

in the incidence of metabolic syndrome with obesity and diabetes has the nature of a pandemic and, without long-term systemic dietary

and regimen measures, its incidence cannot be reduced.

Keywords: insulin resistance, hypertension, obesity, nephropathy

Published: June 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Teplan V. Metabolic syndrome in nephrology. Med. praxi. 2010;7(5):209-215.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Doelle GC. Klinický obraz metabolického syndromu. Medicína po promoci 2004; 5: 5-11.
    2. Kahn R, Buse J, Ferrannmi, Stem M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304. Go to original source... Go to PubMed...
    3. Masopust J. Metabolický syndrom. Pohybové ústrojí, 2005; 12(3-4): 148-182.
    4. Axelsson J, Heimbürger O, Lindholm B, et al. Adipose tissue and its relation to inflammation: the role of adipokines, J Renal Nutr 2005; 15(1): 131-136. Go to original source... Go to PubMed...
    5. Wiecek A, Kokot F, Chudek J, et al. The adipose tissue - a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transpl 2002; 17(Suppl. 2): 191-195. Go to original source... Go to PubMed...
    6. Andrlová K, Haluzík M. Tuková tkáň a inzulinová rezistence. Diab Met Endrokrin. Výživa 2005; 8(2): 87-96.
    7. Mak RH, Cheung W, Cone RD, et al. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int 2006; 69: 794-797. Go to original source... Go to PubMed...
    8. Chudek J, Adamaczak M, Karozska H, et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transpl Proc 2003; 35(6): 2186-2189. Go to original source... Go to PubMed...
    9. Zoccali C, Mallamaci F, Tripeppi G. Adipose tissue as a source of inflammatory cytokines in health and disease: Focus and-stage renal disease. Kidney Int 2003; 63(Suppl 84): 65-68. Go to original source... Go to PubMed...
    10. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol 2006; 17: S81-S85. Go to original source... Go to PubMed...
    11. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hyperensive patients with and without the metabolic syndrome. (ALLHAT). Arch Intern Med 2008; 168: 207-217. Go to original source... Go to PubMed...
    12. Boger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab med 2003; 41(11): 1467-1472.
    13. Ritz E, Wanner C. Lipid changes and statins in chronic renal insufficiency. J Am Soc Nephrol 2006; 17: S 226-S 230. Go to original source... Go to PubMed...
    14. Tsimihodimos V, Dounousi E, Siamopoulos K. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008; 28: 958-973. Go to original source... Go to PubMed...
    15. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41: I-IV, S1-S91.
    16. Kwan BC, Kronberg F, Bedhu S, et al. Lipoproein metabolism and lipid management in chronic kidney disease. J Am Soc 2007; 18: 1246-1261. Go to original source...
    17. Klassen A, Sebekova K, Heidland A, et al. Obesity - a neglected risk factor of the kidney Nieren - und Hochdruckkrankheiten 2003; 32(5): 189-196.
    18. Kincaid-Smith P. Hypothesis: Obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labeled hypertensive nephrosclerosis. J Hypertens 2004; 22: 1051-1055. Go to original source... Go to PubMed...
    19. Iseki K, Ikemyira Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease. Kidney Int 2004; 65: 1870-1876. Go to original source... Go to PubMed...
    20. Chen J, Munter P, Hamm L, et al. The metabolic syndrome and chronic kidney disease in U. S. adults. Ann Intern Med 2004; 140: 167-174. Go to original source... Go to PubMed...
    21. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc nephrol 2003; 14: 469-477. Go to original source... Go to PubMed...
    22. Praga M, Hernandez E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000; 58: 2111-2118. Go to original source... Go to PubMed...
    23. Praga M, Hernandez MA, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transpl 2001; 16: 1790-1798. Go to original source... Go to PubMed...
    24. Rea DJ, Heimbach JK, Grande JP, et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int 2006; 70: 1636-1641. Go to original source... Go to PubMed...
    25. Hall JE, Henegar JR, Dwyer TM, et al. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther 2004; 11: 41-54. Go to original source... Go to PubMed...
    26. Teplan V, Schück O, Racek J, Lecian D, Haluzik M, Kudla M, Vítko Š. Asymmetric dimethylarginine in obesity after renal transplantation. J Renal Nutrition 2008; 18: 513-520. Go to original source... Go to PubMed...
    27. Kielstein JT, Frölich JC, Haller H, Fliser D. ADMA: an atherosclerotic disease mediating agens in patients with renal disease? Nephrol Dial Transplant, 2001; 16: 1742-1745. Go to original source... Go to PubMed...
    28. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008; 73: 19-33. Go to original source... Go to PubMed...
    29. Taylor EN, Stampfer MU, Curham GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293: 455-462. Go to original source... Go to PubMed...
    30. Ejerblad E, Fored M, Lindblad, et al. Obesity snd risk of chronic renal failure. J Am Soc nephrol 2006; 17: 1695-1702. Go to original source... Go to PubMed...
    31. Speckman RA, McClellan WM, Volkova NV, et al. Obesity is associated with family history of ESRD in incident dialysis patients. Am J Kidney Dis 2006; 48: 50-58S. Go to original source... Go to PubMed...
    32. Kambham N, Markowitz GS, Valeri MM, et al. Obesityrelated glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509. Go to original source... Go to PubMed...
    33. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in IgA nephritis. Am J Kidney Dis 2001; 37: 720-729. Go to original source... Go to PubMed...
    34. Kramer HJ, Saranathan A, Luke A, et al. Increased body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453-1459. Go to original source... Go to PubMed...
    35. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome links to chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 550-562. Go to original source... Go to PubMed...
    36. Bergstrom A, Hsieh CC, Lindblad P, et al. Obesity and cell cancer-a quantitative review. Br J Cancer 2001; 85: 984-990. Go to original source... Go to PubMed...
    37. Ducloux D, Kazory A, Simula-Faivre D, Chalopin JM. Oneyear post-transplant weight gain is a risk factor for graft loss. Am J Transplant 2005; 5: 2922-2928. Go to original source... Go to PubMed...
    38. Di Iorgi N, Rosol M, Mittelman SD, et al. Reciprocal relation between bone marrow adiposity and the amount of bone in skeleton of adults. J Clin Endocrin Metabol 2008; 93: 2281-2286. Go to original source... Go to PubMed...
    39. Axelsson J. The emerging biology of adipose tissue in chronic kidney disease: from fat to facts. Nephrol Dial Transpl 2008; 23: 3041-3046. Go to original source... Go to PubMed...
    40. Hilgers KF, Mann FE. The choice of antihypertensive therapy in patients with the metabolic syndrome - time to change recommendations? Nephrol Dial Transplant 2008; 23: 3389-3391. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.